Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA expands use for ArthoCare's RF (radiofrequency) tools:

This article was originally published in Clinica

Executive Summary

ArthroCare has received US FDA marketing clearance to expand the use of its radiofrequency (RF) arthroscopic surgical devices. The Sunnyvale, California firm has gained the go-ahead to use its Coblation-based disposable surgical devices in over 40 specific arthroscopic indications in the knee, shoulder, wrist, ankle, elbow and hip. The expanded clearance covers around 160 orthopaedic procedures and represents the broadest array of specific indications approved for any company marketing RF surgical equipment for arthroscopic and orthopaedic applications, the company claims. The devices were previously cleared for soft tissue resection, ablation, coagulation and haemostasis in general arthroscopic and orthopaedic procedures.

You may also be interested in...

Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says

Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.

Sanofi Grapples With Pandemic, Growing Clinical Trials, Implementing Acquisitions

Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.

ATAI Raises $125m Series C To Expand The Boundaries In Mental Health

The funding will be used to support clinical and preclinical development at its portfolio companies, with 8-10 programs in the clinic in 2021.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts